Clin2
NCT03827876Possibly a fitRecruiting

Enstilar added to Enbrel or Humira for plaque psoriasis

Psoriasis

Part of Skin clinical trials.

This trial tests whether adding Enstilar (a skin spray/foam medication) on top of your usual injection—Enbrel or Humira—works better for plaque psoriasis. You might be a candidate if your psoriasis affects a moderate amount of skin and you’ve been on Enbrel or Humira long enough.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
30 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You’re an adult age 18 or older.
  • You have chronic plaque psoriasis.
  • Your psoriasis covers about 2% to 10% of your body surface area.
  • Your physician rates your skin severity as 2 or higher.
  • You have been using Enbrel (etanercept) or Humira (adalimumab) for at least 24 weeks.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT04372277Recruiting· Phase 4
Adding Enstilar to Taltz for plaque psoriasis

This trial studies whether using Enstilar (a medicated skin spray/foam) together with Taltz works better than staying on Taltz alone for chronic plaque psoriasis. It focuses on adults with a specific amount of body skin affected by psoriasis who have already been on Taltz for at least 24 weeks.

East Windsor, New Jersey
NCT04347473Recruiting· Phase 4
ILUMYA plus halobetasol ointment for plaque psoriasis

This trial studies whether ILUMYA (an injection) working together with halobetasol ointment helps control moderate-to-severe plaque psoriasis. It is meant for adults whose psoriasis is significant enough that they may need light therapy (phototherapy) and/or pills/injections (systemic therapy).

East Windsor, New Jersey
NCT06477237Recruiting· Phase 3
Testing a new psoriasis shot for moderate to severe plaque

This trial tests a new medication called HB0017 for moderate to severe plaque psoriasis. It aims to see if it is safe and effective in reducing skin symptoms and improving quality of life.

Jiangmen, Guangdong
NCT07204639Recruiting· Phase 2
Testing CBP-0276 for moderate to severe psoriasis

This trial tests a new medication, CBP-0276, to see if it improves psoriasis symptoms and quality of life. It is for people with moderate to severe plaque psoriasis who might need stronger treatment.

Mexico City
NCT07719530Recruiting· Phase 2
Testing SHR-1139 injection for moderate to severe psoriasis

This study tests a new injection called SHR-1139 for people with moderate-to-severe plaque psoriasis. The goal is to see if it can safely improve your skin condition.

Guangzhou, Guangzhou
NCT06672393Not yet recruiting· Phase 3
Testing HS-10374 for moderate to severe plaque psoriasis

This study tests an investigational oral medication called HS-10374 for moderate to severe plaque psoriasis. It aims to see how well it clears skin and prevents flares compared to a placebo, and if it is safe for long-term use.

Shanghai, Shanghai Municipality

Hear when a new Psoriasis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.